INTRODUCTION
Hematopoietic stem/progenitor cell (HSPC)-based gene therapy to reconstitute an HIV-1-infected patient's immune system with genetically engineered, HIV-resistant HSPCs and their progenies has the potential to provide a long-term HIV-1 control without daily drug treatment or to achieve an HIV/AIDS cure. [1] [2] [3] [4] [5] [6] [7] Similar to the one case of an HIV-1 cure achieved by transplants of CCR5D32/D32 homozygous HIV-1-resistant donor bone marrow (BM) cells in an HIV-infected patient, [8] [9] [10] [11] anti-HIV-1 HSPC gene therapy aims to treat an HIV-1-infected patient by repopulating HIV-1-resistant HSPCs and their progenies.
Various anti-HIV-1 genes have been developed to genetically protect human CD34 + HSPCs and their progenies. 4, 5, [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] Previously, in vivo investigations of these anti-HIV-1 genes have been performed by viral challenge after transplantation of anti-HIV-1 gene-modified HSPCs in immunodeficiency mice. 15, [30] [31] [32] [33] [34] [35] [36] [37] [38] The experimental design allowed us to examine the engraftment of anti-HIV-1 gene-modified HSPCs without confounding HIV-1 pathogenic effects. Subsequently, the mice are challenged with HIV-1 to examine the protection of anti-HIV-1 gene-modified immune cells. Using this protocol, we demonstrated that human CD34 + HSPCs transduced by an anti-HIV-1 lentiviral vector expressing dual short hairpin RNAs (shRNAs) targeting CCR5 (sh1005) and HIV-1 long terminal repeat (LTR) (sh516) successfully reconstituted anti-HIV-1 vector-modified multi-lineage hematopoietic cells in humanized BM , liver, and thymus (BLT)-transplanted mice; we also demonstrated the selective advantage of the anti-HIV-1 dual shRNA gene expressing CD4 + T lymphocytes after an HIV-1 challenge in the reconstituted mice. 15 However, it is unknown whether the anti-HIV-1 gene-modified HSPCs can engraft, differentiate into mature hematopoietic cells, and be protected in humanized mice previously infected with HIV-1.
In this report, our primary goal was to establish a new method to examine an anti-HIV-1 HSPC-based gene therapy strategy in humanized mice previously infected with HIV-1. First, we prepared humanized mice by transplanting human fetal liver-derived CD34 + HSPCs into irradiated neonatal NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ (NSG) mice. Humanized mice were subsequently infected with HIV-1. When plasma viremia reached >10 7 copies/mL, HIV-1-infected humanized mice were preconditioned with busulfan and transplanted with anti-HIV-1 gene-modified, human fetal liver-derived CD34 + HSPCs and human thymus tissue from the same donor to repopulate HIV-1-resistant, gene-modified immune cells in lymphoid organs in the HIV-1 previously infected humanized mice. Using this new experimental method, we evaluated the engraftment of the dual shRNAs, CCR5 (sh1005) and HIV-1 LTR (sh516), modified HSPCs, differentiation into mature hematopoietic cells, tissue reconstitution, and the selective advantage of CD4 + T lymphocytes in the HIV-1 previously infected humanized mice.
RESULTS

Preparation of HIV-1-Infected Humanized NSG Mice
We investigated a new method to test anti-HIV-1 HSPC-based gene therapy in humanized mice previously infected with HIV-1 ( Figure 1 Figure 2 , lower panels). Group 1 mice (n = 11) were infected with CCR5-tropic HIV-1 NFNSX (200 ng of p24 Gag) intravenously via retro-orbital vein plexus 11 weeks after CD34 + HSPC transplant. Group 2 mice (n = 12) were used as a non-HIV-1-infected control. Plasma viral load reached an average of 1.25 Â 10 7 copies/mL ± 1.48 Â 10 7 SD 3 weeks after HIV-1 injection.
Transplantation of Anti-HIV-1 Gene Vector-Transduced HSPCs in HIV-1 Previously Infected Humanized Mice HIV-1-infected (n = 11) and HIV-1-uninfected (n = 12) humanized mice were myeloablated by an intraperitoneal injection of busulfan (35 mg/kg) 3 weeks after HIV-1 injection. To avoid potential problems caused by human leukocyte antigen (HLA) mismatch, cryopreserved, human fetal liver-derived CD34 + HSPCs from the same donors were thawed and transduced with the anti-HIV-1 dual shRNA sh1005/sh516 vector (EGFP marked) or the were transduced with a control lentiviral vector expressing mCherry without shRNA. Transduced CD34 + HSPCs were mixed after the vector transduction and transplanted by a retro-orbital vein plexus injection and with a piece of human thymus under the mouse kidney capsule. Reconstitution of vector-modified human hematopoietic cells was examined in peripheral blood 6-10 weeks and in lymphoid tissues 12 weeks after vector-modified CD34 + HSPC transplant.
no-shRNA control vector (mCherry marked). After vector transduction overnight, vector-transduced cells (0.5 Â 10 6 cells) were mixed at a 1:1 ratio and transplanted intravenously via retroorbital vein plexus, along with a cryopreserved, donor-matched human thymus tissue piece under the kidney capsule to create a human thymus implant, as previously described. 15, 28, 34, 39, 40 The efficiencies of vector transduction in CD34 + HSPCs (n = 5) were determined by %EGFP expression at 72.92 ± 10.84 (% ± SD) and by %mCherry expression at 73.28 ± 18.98 (% ± SD) in an aliquot culture with cytokine stimulation (stem cell factor [SCF], interleukin-3 [IL-3], and IL-6 at 50 ng/mL each) 3 days after vector transduction. Kinetics of %EGFP and %mCherry expressing CD4 + T lymphocytes were monitored in peripheral blood from 6 to 10 weeks after vector-modified CD34 + HSPC transplant. %EGFP increased more than %mCherry in CD4 + T lymphocytes in the HIV-1 previously infected humanized mice (p ˂ 0.0001, group-time interaction from a linear mixed-effects model) ( Figure 4B ). There were no significant differences in the kinetics of %EGFP and %mCherry expression in CD4 + T lymphocytes in HIV-1-uninfected humanized mice ( Figure 4A ) and CD8 + T lymphocytes in both uninfected and HIV-1 pre-infected humanized mice (p > 0.05, group-time interaction from a linear mixed-effects model) ( Figures 4C and 4D ). We then analyzed tissue repopulation 12 weeks after vector-modified CD34 + HSPC transplant. The mean %EGFP was higher than the mean %mCherry + in CD4 + T lymphocytes in BM, lung, and gut in the HIV-1 previously infected humanized mice ( Figure 5 ; Figure S1 ), suggesting that anti-HIV-1 dual sh1005/sh516 vector-modified CD4 + T lymphocytes were positively selected by HIV-1-induced selective pressure in HIV-1 previously infected humanized mice. Viral load, however, was maintained in all HIV-1 previously infected humanized mice 12 weeks after anti-HIV-1 gene vector-modified CD34 + HSPC transplant (2.35 Â 10 7 ± 4.10 Â 10 7 copies/mL ± SD). Because each animal was reconstituted with not only EGFP + anti-HIV-1 gene vectormodified cells, but also cells marked with mCherry no-shRNA control vector and unmodified cells, the maintenance of viral load was expected. Altogether, these results demonstrated anti-HIV-1 dual sh1005/sh516 vector-modified HSPCs were able to engraft and + T lymphocytes in tissues in HIV-1-uninfected humanized mice ( Figure 6 ; Figure S2 ), similar to our previously published results. 15, 28 In humanized mice previously infected with HIV-1, CCR5 expression was reduced in EGFP + CD4 + T lymphocytes. In addition, CCR5 expression was reduced in control mCherry + CD4 + T lymphocytes. This could be due to HIV-1-mediated depletion of unprotected mCherry + CD4 + T lymphocytes in HIV-1 previously infected humanized mice. Therefore, we did not observe a difference in relative CCR5 expression levels in EGFP + and mCherry + CD4 + T lymphocytes.
DISCUSSION
In this study, we developed a new method to test an anti-HIV-1 HSPC-based gene therapy in HIV-1 previously infected humanized mice. The practical clinical application of anti-HIV-1 HSPC-based gene therapy is to treat HIV-1-infected patients. 5, [41] [42] [43] [44] Thus, it is important to examine anti-HIV-1 HSPC-based gene therapy strategies in animals already infected with HIV-1.
In our new method, we first infected humanized mice with HIV-1. After the establishment HIV-1 infection, determined by viremia, HIV-1-infected humanized mice were treated with busulfan for myeloablative conditioning and transplanted with anti-HIV-1 were comparable to our previously published post-infection results. 15, 28, 34 Our new results demonstrated that the anti-HIV-1 dual sh1005/sh516 vector-modified HSPCs successfully engrafted and differentiated into the HIV-1-resistant progeny CD4 + T cells and then selected from HIV-1-induced T cell loss in humanized mice already infected with HIV-1. To our knowledge, this is the first study to present successful engraftment of anti-HIV-1 gene-modified human HSPCs in HIV-1-infected humanized mice.
Accumulated evidence suggests that the current anti-retroviral drug therapy cannot provide a cure for AIDS. [45] [46] [47] Thus far, the first and only clinical cure of HIV/AIDS was achieved by transplants of CCR5D32/D32 homozygous HIV-1-resistant donor BM cells. [8] [9] [10] [11] However, wider clinical application of such a protocol is impractical due to scarcity of HLA-matched allogeneic CCR5D32/D32 homozygous BM donors. 48, 49 Autologous HSPC-based gene therapy can eliminate the need for finding HLA type-matched allogeneic CCR5D32/D32 homozygous BM donors. It has a potential to develop as a novel therapeutic strategy for an HIV-1 cure. To better evaluate the potential of anti-HIV-1 HSPC-based gene therapy strategies, it is desirable to examine in a clinically relevant setting. Our newly developed method to reconstitute HIV-1 already infected humanized mice with anti-HIV-1 gene-modified HSPCs will be a useful tool to investigate various anti-HIV-1 HSPC-based gene therapy strategies in vivo in an experimentally tractable, small animal model system.
MATERIALS AND METHODS
Human CD34 + HSPCs and Fetal Tissue
Human fetal thymuses and fetal livers were obtained from Advanced Bioscience Resources (ABR), FPA Women's Health, and the UCLA www.moleculartherapy.org
Center for AIDS Research (CFAR) Gene and Cellular Therapy Core. The UCLA institutional review board has determined that these tissues are not human subjects and do not require an institutional review board review, because fetal tissues were obtained without patientidentifying information from deceased fetuses. Written informed consent was obtained from patients for the use of tissues in research purposes. CD34 + HSPCs were isolated from fetal livers using anti-CD34 + magnetic bead-conjugated monoclonal antibodies (Miltenyi Biotec) and cryopreserved in Bambanker (Wako Chemical USA). 28 Human thymus pieces from the same donor were cryopreserved in 10% DMSO (Sigma-Aldrich) in human AB serum and stored in liquid nitrogen, as previously published. 39 They were thawed at 37 C in a water bath before use. 
HIV-1 Infection
CCR5-tropic HIV-1 NFNSX stocks were prepared by a calcium phosphate plasmid DNA transfection method as previously described. 28 Humanized NSG mice were injected with HIV-1 NFNSX (200 ng of p24 Gag) via the retro-orbital vein plexus using a 27-gauge needle.
Viral Load Assay
Levels of HIV-1 RNA in plasma of infected humanized mice were determined by RT-PCR assay. 100 mL of whole blood was harvested via the retro-orbital vein plexus 3 weeks after HIV-1 injection. Approximately 50 mL of plasma was separated from peripheral blood and stored at À80 C until use. Viral RNA was isolated with a QIAamp viral RNA mini kit (QIAGEN). The RNA was eluted in 25 mL of RNase-free water, and 5 mL of elution was applied for qRT-PCR using an iScript One-step RT-PCR kit (Bio-Rad), with the following primers and probe specific to HIV-1 NFNSX gag region: primer sequence 1, 5 0 -CCCTACCAGCATTCTGGACATAAG-3 0 ; primer sequence 2, 5 0 -GCTTGCTCGGCTCTTAGAGTT-3 0 ; and probe 5 0 -FAM-ACAAGGACCAAAGGAACCCTT-BHQ1-3 0 . With these primers and probe, HIV-1 RNA can be quantitatively detected from 10 3 to 10 8 copies/mL.
Lentiviral Vector Production
Vesicular stomatitis virus G protein (VSVG)-pseudotyped lentiviral vector stocks were produced by calcium phosphatemediated transient transfection of HEK293T cells, as previously described. 15, 28, 34 Vector stocks were titered on HEK293T cells based on EGFP or mCherry expression analyzed by flow cytometric analysis.
Lentiviral Vector Transduction
The cryopreserved, fetal liver-derived CD34 + HSPCs (0.5 Â 10 6 ) were thawed and seeded into 20 mg/mL RetroNectin (Clontech Laboratories)-coated plates with 2% BSA (Sigma-Aldrich) in Yssel's medium (GEMINI Bio Products). After 1 hr of incubation, cells were transduced with either anti-HIV-1 dual sh1005/sh516 (MOI = 3) or noshRNA control lentiviral vector (MOI = 1) overnight without cytokine stimulations to achieve the similar transduction efficiency measured by %EGFP or %mCherry expression, respectively. An aliquot of each transduced CD34
+ HSPC was cultured in RPMI 1640 (Gibco) with 10% fetal bovine serum (HyClone), supplemented with cytokine stimulations (SCF, IL-3, and IL-6; all three from PeproTech) at a concentration of 50 ng/mL for 3 days. The efficiencies of vector transduction were evaluated by flow cytometry (Fortessa flow cytometers, BD Biosciences). After transduction, vector-transduced CD34 + HSPCs were mixed at a 1:1 ratio for transplantation into mice. ) using a 27-gauge needle through the retro-orbital vein plexus.
Flow Cytometry
Isolation of peripheral blood mononuclear cells (PBMCs) and cells from the BM, lung, gut, spleen, and human thymus implant were described previously. 28 Peripheral blood-and tissue-derived mononuclear cells were stained with monoclonal antibodies to human CD45-eFluor 450 (HI30, eBioscience), CD3-APC H7 (SK7, Pharmingen), CD4-APC (OKT4, eBioscience), and CD8-PerCP Cy5.5 (SK1, BioLegend), CD19-Brilliant Violet 605 (HIB19, BD Horizon), and CCR5-PECy7 (2D7, Pharmingen). Red blood cells were lysed with red cell lysis buffer after cell surface marker staining. Stained cells were fixed with 1% formaldehyde in PBS and examined with Fortessa flow cytometers (BD Biosciences). The data were analyzed by FlowJo v.10 (Tree Star) software.
Statistical Analysis
A linear mixed-effects model was used to evaluate differences in logtransformed EGFP or mCherry marker intensity levels by HIV status at (1) baseline and (2) over time in Figure 4 . The difference between groups and time was evaluated using a group-time interaction, and the p value for this interaction was calculated using a likelihood ratio test comparing the models with and without the interaction term. Given that there were three time points, time was modeled as a categorical variable. A compound symmetry correlation structure was used for all models. The paired Student's t test was used for other statistical analysis. Statistical significance was evaluated as *p < 0.05. We indicate other significance levels as follows: **p < 0.01, ***p < 0.001, and ****p < 0.0001. Statistical analyses were performed using GraphPad Prism.
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